Skip to main content

Table 2 Summary of key unit costs

From: Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort

  Unit cost Source
Inpatient stay
 Spell cost £797 National Tariff 2013/14
 Cost per excess bed day £243 National Tariff 2013/14
Outpatient visit
 First attendance (single profession) £247 National Tariff 2013/14
 First attendance (multi-profession) £248 National Tariff 2013/14
 Follow-up visit (single profession) £113 National Tariff 2013/14
 Follow-up visit (multi-profession) £174 National Tariff 2013/14
Diagnostic procedures
 Diagnostic biopsy £260 National Tariff 2013/14a
 Staging biopsyb £503 National Tariff 2013/14
Imaging
 Computed tomography (CT) £105 National Tariff 2013/14
 Magnetic resonance imaging (MRI) £206 National Tariff 2013/14
 Positron emission tomography (PET) £748 National Tariff 2013/14
 Ultrasound £51 National Tariff 2013/14
 Electrocardiography (ECG) £172 National Tariff 2013/14
 Echocardiography (Echo) £322 National Tariff 2013/14
Radiotherapy
 Planning £769 National Tariff 2013/14
 Per fraction £123 National Tariff 2013/14
Chemotherapy (per cycle)
 CHOP £289 Leeds Teaching Hospitals Trust
 R-CHOP £1730 Leeds Teaching Hospitals Trust
 R-CVP £1486 Leeds Teaching Hospitals Trust
 CODOX-M/IVAC-R £6241 Leeds Teaching Hospitals Trust
 IDARAM £2006 Leeds Teaching Hospitals Trust
 R-DHAP £1952 Leeds Teaching Hospitals Trust
 R-ESHAP £3344 Leeds Teaching Hospitals Trust
 MiniBEAM £446 Leeds Teaching Hospitals Trust
 Methotrexate (low dose intrathecal) £5 Leeds Teaching Hospitals Trust
 Methotrexate (high dose) £861 Leeds Teaching Hospitals Trust
Autologous stem-cell transplant (ASCT) £42,000 Leeds Teaching Hospitals Trust
  1. CHOP cyclophosphamide, doxorubicin, vincristine and prednisone, R-CHOP cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab, R-CVP cyclophosphamide, vincristine, prednisone and rituximab, CODOX-M/IVAC-R cyclophosphamide, doxorubicin, vincristine, methotrexate/ifosfamide, etoposide, high dose cytarabine and rituximab, IDARAM rituximab, idarubicin, dexamethasone, cytarabine and methotrexate, R-DHAP dexamethasone, cytarabine, cisplatin and rituximab, R-ESHAP etoposide, methylprednisolone, cytarabine, cisplatin and rituximab, MiniBEAM carmustine, etoposide, cytarabine and melphalan
  2. aAverage of National Tariffs 2013/14
  3. bIncluding: BMAT bone marrow aspirate and trephine, BMA bone marrow aspirate and TB bone marrow trephine